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Due to the prominent angiogenesis that occurs in malignant glioma, antiangiogenic therapy has been attempted. There have been
several molecular targets that are speciﬁc to malignant gliomas, as well as more broadly in systemic cancers. In this review, I will
focus on some topics related to molecular therapeutic targets for glioma angiogenesis. First, important angiogenic factors that
could be considered molecular targets are VEGF, VEGF-induced proteins on endothelial cells, tissue factor, osteopontin, αvβ3
integrin, and thymidine phosphorylase as well as endogenous inhibitors, soluble Flt1, and thrombospondin 1. Second, hypoxic
areas are also decreased by metronomic CPT11 treatment as well as temozolomide. Third, glioma-derived endothelial cells that
are genetically and functionally distinct from normal endothelial cells should be targeted, for example, with SDF-1 and CXCR7
chemokine. Fourth, endothelial progenitor cells (EPCs) likely contribute towards glioma angiogenesis in the brain and could be
useful as a drug delivery tool. Finally, blockade of delta-like 4 (Dll4) results in a nonfunctioning vasculature and could be another
important target distinct from VEGF.
1.Introduction
Malignant gliomas tend to be highly vascularized and con-
tain hypoxic regions. Therefore, an antiangiogenic strategy
is promising for malignant gliomas [1, 2]. In this review,
I focus on some molecular therapeutic targets for glioma
angiogenesis:(1)angiogenicfactors,(2)hypoxia,(3)glioma-
derived endothelial cells, and (4) resistance to antiangiogenic
therapy. The problem of how to treat patients who fail to
respond to antiangiogenic therapy remains a challenge, and
themechanismsofresistancearebeingstudied.Thepotential
mechanisms by which tumor cells can evade antiangio-
genic therapy include upregulation of non-VEGF-mediated
pathways of angiogenesis, recruitment of bone marrow-
derived cells, increased pericyte coverage, and increased use
of preexistent vasculature by invasion [3].
2. AngiogenicGrowth Factorsin Glioblastoma
Vascular endothelial growth factor (VEGF) is a major
angiogenic factor in glioblastoma [4]. VEGF is localized
within tumor cytoplasm and endothelium (Figure 1). VEGF
is predominantly located in the perinecrotic area, which
is referred to as the pseudopallisading area and appears
to be hypoxic. By contrast, there are few VEGF positive
cells in low-grade astrocytomas and no VEGF positive cells
in the normal brain. We initially demonstrated increased
expression of VEGF in malignant glioma tissues, with
both ELISA (Figure 2) and immunohistochemistry. We also
demonstrated high VEGF protein concentrations in the cyst
ﬂuidfromglioma,butVEGFwasnotdetectableintheserum.
VEGF-related angiogenic factors have been also clearly
demonstrated in glioma tissues by RT-PCR and immunohis-
tochemistry. Tissue factor is highly expressed in malignant
gliomas associated with VEGF expression (Figure 3)[ 5].
Also, osteopontin and αvβ3 integrin, which are also induced
by VEGF in endothelium, are predominantly expressed in
tumor endothelium. Another angiogenic factor, thymidine
phosphorylase, is also only expressed in malignant gliomas,
but not in low-grade glioma or normal brain (Figure 4)[ 6].
Endogenous angiogenesis inhibitors are important
molecules in the delicate balance of angiogenic potential in
tumors. The soluble form of the VEGF receptor 1 (sFlt-1)
is a measurable, potent, and speciﬁc VEGF inhibitor. The2 Journal of Oncology
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Figure1:VEGFlocalizationingliomas.(a)–(c)Glioblastoma.VEGFlocalizesinthecytoplasmofthetumorcellsandtumorcapillaryaround
the necrosis and the tumor periphery. (d) Anaplastic astroctytoma. (e) Diﬀuse astrocytoma. (f) Normal brain. Original magniﬁcation (a, c)
×5 0 ,( b ,d ,e ,f)×200.
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Figure 2: VEGF concentration in the various brain tumors.
concentrations of sFlt-1 and VEGF have been measured in
glioma tissues by ELISA. A VEGF/sFlt-1 ratio greater than 1
is a worse prognostic factor in glioblastomas (Figure 5)[ 7].
The signiﬁcance of the VEGF/sFlt-1 ratio as a prognostic
factor is greater than for the VEGF concentration alone,
suggesting that the angiogenic balance between angiogenic
factor and its inhibitor is important in tumor angiogenesis.
Experimentally,transfectionofhumangliomacellswithsFlt-
1 demonstrated low expression of VEGF mRNA compared
to transfection with an empty vector. The tumor growth of
these sFlt-1 transfectants was inhibited, but the inhibitory
activity was limited [7]. Another endogenous angiogenic
inhibitor, thrombospondin1 (TSP1), was introduced into
human U87 glioma cells by transfection (Figure 6). The
glioma growth of the TSP1 transfectant was signiﬁcantly
inhibited compared to those of parent and vector-alone
transfectants (Figure 7)[ 7]. These clinical and experimental
data support the importance of angiogenic balance as a keyJournal of Oncology 3
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Figure 3: Tissue factor and VEGF mRNA expression in human glioma samples. Tissue factor expression was frequent and highly observed
in glioblastomas associating with VEGF expression.
Table 1: Inhibition of angiogenesis in the chick chorioallantoic
membrane assay.
Suramin
(μg/disk)
Embryos
evaluated
(positive/total)
% of inhibition
00 / 1 00
30 0/7 0
250 2/8 25
500 5/10 50
1000 12/17 71
1500 7/7 100
factor in antiangiogenic therapy. This is likely because these
endogenous angiogenesis inhibitors are upregulated in
malignant gliomas, as a consequence of the upregulation of
angiogenic factors.
The general growth factor receptor inhibitor, suramin,
was investigated for its antiangiogenic action [8]. Suramin
inhibitedphysiologicangiogenesisinadose-dependentman-
ner, based on the chorioallantoic membrane (CAM) assay
(Table 1). Suramin inhibited the bFGF-induced endothelial
expression of urokinase-type plasminogen-activator (uPA)
using gelatin zymogram (Figure 8). uPA is closely related to
the initiating step of angiogenesis, degradation of the extra-
cellular matrix. Using a rat intracranial C6 glioma model,
suramin inhibited Ki67 labeling of the tumor endothelium
(Figure 9)[ 9]. All of these data suggest that suramin can
inhibit physiological and tumor angiogenesis at multiple
levels.
Recently, the anti-VEGF antibody, bavacizumab, has
been used in the treatment of glioblastoma [10]. The
growth inhibitory eﬀect is dramatic, especially when deter-
mined with MRI enhancement and MRI perfusion study
[11]. Interestingly, ACNU (1-(4-amino-2-methyl-5-pyrim-
idinyl)-methyl-3-(2-cholroethyl)-3-nitrosourea hydrochlo-
ride) chemotherapeutic agents resulted in upregulation of
VEGF mRNA in glioma cells (Figure 10)[ 12]. A similar
eﬀect on upregulation of VEGF has been demonstrated by
irradiation of glioma cells. Thus, the combination of VEGF
antagonism, that is, VEGF antibody in the initial glioma
therapy, is a reasonable strategy in ACNU chemotherapy
and in radiation therapy (Figure 11). The VEGF antibody is
attractive for attacking tumor stem cells, as a new strategy
to combat glioblastomas, because the VEGF antibody could
inhibit maintenance of glioma stem cells by destroying
glioma vascular niche [13, 14], in contrast to the eﬀects
of radiation or other chemotherapeutics. However, the
antiangiogenic antiglioma eﬀect is transient (Figure 12).
Congruent with the results obtained in orthotropic mouse
models of GBM, four recent clinical studies have implicated
proinvasive adaptation in humans, as observed by MRI,
in a subset of GBM patients who developed multifocal or
diﬀuse recurrence of the tumor during a course of anti-
VEGF therapy with bevacizumab, as in our case [15–17].
Thus, there is a clear need for alternative strategies after
bevacizumab failure.
3. HypoxiainGliomas
Oneofthe mechanisms ofresistancetoangiogenic treatment
isthepresenceofhypoxicregionsingliomatissues.Hypoxia-
inducible factor 1α (HIF1α) is induced by hypoxia and
is upstream of VEGF mRNA expression. Immunohisto-
chemical expression of HIF-1α clearly correlated with the
degree of glioma malignancies and predicted survival among
patients with malignant gliomas (Figure 13) and the degree
of necrosis on MRI (data not shown). Therefore, HIF-
1α has been the focus of antiangiogenic treatment [18].
Downregulation of HIF-1α in glioma cells using siRNA
resulted in growth inhibition and an angiosuppressive
eﬀect on glioma growth (unpublished data). Metronomic
chemotherapy is a promising strategy to overcome resis-
tance to antiangiogenic treatment [19]. We demonstrated
that SN38, the active metabolite of CPT11, exhibited an
antiangiogenic eﬀect (Figure 14). SN38 inhibited HIF-1α
and VEGF mRNA and protein expression of glioma cells
in a dose- and time-dependent manner [20]. Metronomic
CPT11 treatment of gliomas exhibited growth inhibitory
eﬀects without systemic toxicity, that is, through comparison
of body weight loss that was not observed by conventional
CPT11 treatment. Tumor tissues treated with metronomic
CPT11 exhibited decreased expression of HIF-1α protein
and pimonidazole expression, which were indicative of areas
of hypoxia by immunohistochemistry (Figure 15). A recent
advance in glioma chemotherapy is the discovery of temo-
zolomide. Temozolomide is a powerful chemotherapeutic
agent that prolongs overall survival of initial glioblastoma
by up to 2.5 months [21]. More recently, the feasibility
of bevacizumab with radiation therapy and temozolomide4 Journal of Oncology
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Figure 4:Thymidinephosphorylaseimmunohistochemistryinhumangliomas.Glioblastomashowsintenseimmunoreactionforthymidine
phosphorylase both in tumor and endothelial cells (a). Diﬀuse astrocytoma shows no expression (b). Some of the tymidine phosphorylase
positive cells (c) are macrophages ((d) serial section of (c)). Thymidine phosphorylase positive glioblastoma (e) reveals a high apoptotic
index ((f) serial section of (e)), while Thymidine phosphorylase negative glioblastoma (g) reveals a low apoptotic index ((h) serial section of
(g)). Original magniﬁcation ×200.
in newly diagnosed high-grade gliomas has been reported
[22, 23]. Interestingly, temozolomide has an inhibitory
eﬀect on HIF-1α expression and endothelial cell tube
formation [24]. The metronomic temozolomide treatment
is reasonable and clinical results have been demonstrated
[25, 26].
4.Glioma-DerivedEndothelialCells
Many studies focusing on tumor angiogenesis and endothe-
lial biology are based on established normal cells lines that is,
human umbilical vein endothelial cells (HUVECs). Whether
or not tumor endothelial cells and normal endothelial cellsJournal of Oncology 5
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Figure 5: Malignant glioma survival by VEGF/sFlt-1 ratio.
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Figure 6: Characterization of thrombospondin-1 transfected U87.
Thrombospondin-1 expression was markedly elevated in the trans-
fectant (TSP) compared to vector alone (Neo) and parent U87 (P).
Also VEGF expression was decreased in transfectant (TSP).
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Figure 7: Inhibition of glioma growth by thrombospondin-1
transfection. The glioma growth is signiﬁcantly inhibited by
thrombospondin-1 transfectant (TSP-1 transfectant) compared to
parent U87 and vector alone (Neotransfectant).
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Figure 8: Suramin inhibition of bFGF induced endothelial cell
urokinasetypeplasminogenactivatoractivityongelatinzymogram.
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Figure 9: Suramin inhibition of tumor endothelial cell Ki67
labeling.
are genetically and functionally identical remains controver-
sial. Comparisons between tumor-derived and normal ECs
have been made for a variety of systemic tumors [27]. They
have shown that tumor endothelium exhibits a phenotype of
activated ECs, as reﬂected in the high expression of angio-
genic molecules, that is, VEGFR, the angiopoietin receptor
Tie2, and the adhesion molecules ICAM-1, E-selectin, and
CD44.Inrecentpublications,researchershavesuggestedthat
the tumor-associated ECs derived from GBM tissues have
diﬀerent phenotypic and functional properties compared to
normal ECs [28, 29]; these diﬀerences may result in less
eﬀective antiangiogenic therapy if the target molecules are
only expressed in normal blood vessels. Moreover, these
publications have not mentioned the potential for interac-
tions between tumor cells and tumor-derived endothelial
cells. We isolated tumor endothelial cells from human
glioblastoma samples using ﬂow cytometry, cultured them,6 Journal of Oncology
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Figure 10: Elevation of VEGF mRNA expression by ACNU treatment, but not etoposide and CDDP treatment, in human glioma cells (U87
and U251).
0
1000
2000
3000
4000
5000
T
u
m
o
r
v
o
l
u
m
e
(
m
m
3
)
01 0 2 0 3 0 4 0
Days after tumor implantation
Control
ACNU
VEGF Ab
ACNU + VEGF Ab
(a)
0
0.2
0.4
0.6
0.8
1
S
u
r
v
i
v
a
l
r
a
t
e
01 0 2 0 3 0 4 0 5 0 6 0 7 0
Days after tumor implantation
Control
ACNU
VEGF Ab
ACNU + VEGF Ab
(b)
Figure 11: Glioma growth inhibition by VEGF antibody, ACNU, and the combination of both treatments with U87 subcutaneous (a) and
intracranial (b) model.
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Figure 12:ClinicalcourseofacasewithrecurrentmalignantgliomawithbevacizumabandCPT11treatment.After3cyclesenhancedtumor
and perifocal edema is markedly diminished (Bev 2m). However, after 6 cycles T2 high intense tumors regrow with minimal enhancement
(Bev 4m).
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Figure 13: Malignant glioma survival with hypoxia inducible
factor 1α (HIF-1α) expression on immunohistochemistry. HIF-1α
expression is a negative prognostic factor.
and analyzed the genetic diﬀerences between these cell types
and HUVEC regarding the mRNA and protein expression
of angiogenic factors and chemokines. Glioblastoma-derived
endothelial cells (GBMECs) exhibited high expression of
VEGF, SDF-1, and CXCR7 mRNA compared to HUVEC,
and GBMECs exhibited no expression of CXCR4 mRNA
(Figure 16, unpublished data). We are now investigating
functional diﬀerences between GBMECs and HEUVEC as
well as the interaction between GBMECs and glioma cells
using a coculture system. To obtain successful results with
antiangiogenic therapy, tumor endothelial cells should be
targeted in the future.
5. The Role of Endothelial Progenitor Cells
on Tumor Angiogenesis
Another important mechanism of resistance to antiangio-
genic treatment is related to EPCs. EPCs are introduced
into tumor angiogenesis by tumor stimuli from the bone
marrow. We investigated the role of EPCs on glioma angio-
genesis. C6 glioma cells (5 × 106 cells) were stereotactically
implanted into the brain. After 7 days, EPCs (3 × 105 cells)
that were harvested from umbilical cord blood [30]w e r e
intravenously injected via the tail vein. Seven days after the8 Journal of Oncology
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Figure 14: Antiangiogenic eﬀect of SN38, active metabolite of CPT11. Low dose of SN38 (0.01 and 0.1μM) inhibited tube formation of
HUVEC.
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Figure 15: Hypoxia inducible factor 1α expression and hypoxic area with (b, d) and without (a, c) metronomic CPT11 treatment. HIF-1α
expression and hypoxic area around the necrosis of glioma tissue decreased with treatment.Journal of Oncology 9
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Figure 16: Angiogenic factor and chemokine expression in HUVEC and glioblastoma derived endothelial cells (GBMECs). GBMECs show
high expression of VEGF, SDF-1, and CXCR7 compared to HUVEC and no expression of CXCR4.
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Figure 17: Rich vascular network with EPC-injected glioma. The vessel length of EPC-injected tumor (a) is signiﬁcantly longer than those
of control (b).10 Journal of Oncology
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Figure 18: EPC homing to glioma vasculature. 11 days after injection of GFP labeled EPCs, EPCs localize lectin labeled glioma vasculature.
EPC injection, the rats were sacriﬁced and the C6 gliomas
in the brain were ﬁxed and stained with CD31. EPC-injected
C6 glioma demonstrated a large narrow vascular network.
The vessel length is signiﬁcantly longer than EPCs in an
uninjected tumor (Figure 17). Fluoroscopy demonstrated
that GFP-labeled EPCs localized along with lectin-labeled
tumor vessels (Figure 18). This result suggests that EPC
could induce homing to the glioma vasculature and that
this characteristic of tumor vasculature homing is useful
when considering EPCs as drug delivery tools. If the EPCs
contain angiogenesis inhibitors, the angiogenesis inhibitor
is automatically delivered to the tumor vasculature. To date,
this new strategy has not been published.
6. Molecular Targets of Glioma Angiogenesis
inFuture
Finally, the question remains, what are the current possible
target molecules for glioma angiogenesis? Norden et al. [31]
reported some molecules other than VEGF. Among them,
delta-like 4 (Dll4) remains promising, because the mech-
anisms of angiosuppression are quite diﬀerent to those of
VEGF and the role of Dll4 is reciprocal to VEGF [32, 33].
Remarkably, Dll4 and VEGF are the only known genes for
which loss of a single allele results in embryonic lethality
due to failure to form a functional vasculature. Dll4 is
exclusively expressed by endothelial cells; therefore, this
ligand is a potential therapeutic target. Although blocking
Dll4 appears to promote angiogenesis, the neovasculature
is functionally abnormal and it cannot support tumor cell
survival [34]. Preclinical studies have shown that blockade of
Dll4 was eﬀective in inhibiting the growth of tumors that are
resistant to VEGF inhibition [32]. Whereas most of current
antiangiogenesis approaches act through the reduction or
elimination of tumor blood vessels, Dll4 blockade results
in the formation of a nonfunctional vasculature that is
unable to support tumor growth. This paradoxical strategy
for targeting tumors will be the focus of intense research for
years ahead.
Furthermore, the expression of recombinant toxic pro-
teins that speciﬁcally target tumor endothelium appears
to be promising [35]. Fusion proteins directed against
urokinase-type plasminogen-activator receptor (uPAR) may
be appropriate for targeting endothelial cells in the tumor
vasculature compared with normal endothelium, as uPAR
maybepreferentiallyexpressedinproliferatingendothelium.
TheeﬃcacyofproteinDTAT13thatwassynthesizedtotarget
uPAR on the neovasculature and uPAR- and interleukin-
13-expressing glioblastoma cells has been demonstrated on
glioma growth in vitro and in vivo [36].
7. Conclusion
Anti-angiogenesis therapy for malignant gliomas is promis-
ing by not only inhibiting angiogenesis but also through
alterationofthetumormicroenvironment,thatis,thetumor
vascular niche. Moreover, various combinations of strategies
including the development of new molecular targets have
been investigated. Overcoming resistance to antiangiogenic
therapy with minimal side eﬀects should be considered.
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